Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Limonene oxide is a terpene found in cannabis and citrus fruits that is being investigated for its potential as a bronchodilator in the treatment of chronic inflammatory airway diseases such as asthma. Mechanistically, it induces airway smooth muscle (ASM) relaxation by inhibiting the phosphorylation of myosin light chain 20 (pMLC20), a critical regulatory step in muscle contraction. Research presented at ATS 2025 indicates that while limonene oxide can relax pre-contracted tracheal tissues independently, it also shows potential for cooperative effects when combined with beta-2 adrenergic receptor (B2AR) agonists like isoproterenol. The compound is currently in early-stage research led by institutions such as Thomas Jefferson University and Rutgers University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on limonene oxide.